Epistem, a Manchester, UK-based epithelial stem cell vendor, announced this week that it has entered into a research and development collaboration with Novartis to identify drugs and drug targets across a range of undisclosed disease areas.

An Epistem official said this week that the agreement will bring together Epistem's experience with stem cells and its novel therapeutics program with Novartis' experience with disease pathways and bioinformatics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.